Zidovudine (Dozra)
Zidovudine
Novagen Pharma (Pty) Ltd
Every registration of this product has been cancelled.
Registration
- Applicant
- Novagen Pharma (Pty) Ltd
- Registrations
- 4
- Schedule source
- Consolidated Schedules 06 July 2026
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Dozra 100 MG EACH CAPSULE CONTAINS ZIDOVUDINE 100,0 mg | 100 mg | 41068041/20.2.8/0680 | Cancelled | S4 | None |
| Dozra 250 MG EACH CAPSULE CONTAINS ZIDOVUDINE 250,0 mg | 250 mg | 41068141/20.2.8/0681 | Cancelled | S4 | None |
| Dozra 300 MG tablets EACH TABLET CONTAINS ZIDOVUDINE 300,0 mg | 300 mgTablets | A400383A40/20.2.8/0383 | Cancelled | S4 | None |
| Dozra 50 mg/5 ML oral solution EACH 5,0 ml SOLUTION CONTAINS ZIDOVUDINE 50,0 mg | 50 mg/5 mlOral solution | A400562A40/20.2.8/0562 | Cancelled | S4 | None |
Regulatory status
Where S4 sits on the scale
Prescription-only medicine.
Schedule 4 covers most ordinary prescription medicines. You need a prescription from an authorised prescriber, such as a doctor or dentist, and a pharmacist dispenses it. Its price, name, pack size and strength can still be told to the public, as long as nothing links it to what it treats.
Schedule S4, matched to the Consolidated Schedules by ingredient, confidence high.
Who may supply: A pharmacist dispensing against a written or verbal prescription from an authorised prescriber; a veterinarian, who may also prescribe, compound or dispense it directly; a medical practitioner or dentist, who may prescribe it and may compound or dispense it directly only if licensed under section 22C(1)(a); manufacturers and wholesalers may supply people who may lawfully possess it; and, for animal treatment, a person practising a para-veterinary profession, on a veterinarian's written or verbal instruction.
Consolidated Schedules listings for Zidovudine
S4: Zidovudine
Consolidated Schedules 06 July 2026, line 8412
Pharmacological class: Antiviral agents. (class 20.2.8)
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
1-[(2R,4S,5S)-4-Azido-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione
Drag to rotate. Structure from PubChem CID 35370.
SAHPRA documents
SAHPRA has not published a professional information or patient information leaflet for this product.